|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RGS22 |
Gene summary for RGS22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RGS22 | Gene ID | 26166 |
| Gene name | regulator of G protein signaling 22 | |
| Gene Alias | CT145 | |
| Cytomap | 8q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q8NE09 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26166 | RGS22 | ATC13 | Human | Thyroid | ATC | 7.40e-31 | 5.11e-01 | 0.34 |
| 26166 | RGS22 | ATC5 | Human | Thyroid | ATC | 1.12e-33 | 5.68e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RGS22 | SNV | Missense_Mutation | c.214N>G | p.Leu72Val | p.L72V | Q8NE09 | protein_coding | deleterious(0.01) | benign(0.063) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| RGS22 | SNV | Missense_Mutation | c.2341G>A | p.Asp781Asn | p.D781N | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RGS22 | SNV | Missense_Mutation | rs778928759 | c.383N>C | p.Arg128Thr | p.R128T | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| RGS22 | SNV | Missense_Mutation | rs367712644 | c.3068N>A | p.Arg1023His | p.R1023H | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RGS22 | SNV | Missense_Mutation | novel | c.2748N>A | p.Phe916Leu | p.F916L | Q8NE09 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RGS22 | SNV | Missense_Mutation | novel | c.945N>G | p.Phe315Leu | p.F315L | Q8NE09 | protein_coding | tolerated(0.07) | benign(0.184) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RGS22 | SNV | Missense_Mutation | novel | c.1214G>T | p.Arg405Met | p.R405M | Q8NE09 | protein_coding | deleterious(0.01) | possibly_damaging(0.533) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RGS22 | SNV | Missense_Mutation | rs754379341 | c.2665C>T | p.Arg889Trp | p.R889W | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| RGS22 | SNV | Missense_Mutation | c.2011N>A | p.Glu671Lys | p.E671K | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| RGS22 | SNV | Missense_Mutation | c.456N>T | p.Trp152Cys | p.W152C | Q8NE09 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |